Skip to main content

Market Overview

BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues

BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues
  • BioCryst Pharmaceuticals Inc (NASDAQ: BCRXreported a first-quarter loss of $0.36, wider than the consensus loss of $0.27 and deeper than the EPS loss of $0.24 reported a year ago mainly driven by higher expenses.
  • The company's Q1 sales of $19.10 million beat the consensus estimate of $8.89 million, compared to $4.8 million posted in Q1 of 2020.
  • The increase was primarily due to $10.9 million in Orladeyo net revenue generated in the quarter.
  • R&D expenses increased around 42% Y/Y to $42.4 million, primarily due to increased investment in the development of BCX9930, its oral Factor D inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.
  • SG&A reached $22.1 million up 39% Y/Y due to higher investment to support the U.S. commercial launch of Orladeyo and expanded international operations.
  • Q1 cash and equivalents totaled $244.4 million are expected to support operations into 2023.
  • The company did not provide specific revenue or operating expense guidance.
  • Price Action: BCRX shares rose 21.1% at $12.93 in the market trading hours on the last check Thursday.

Related Articles (BCRX)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech Earnings News Guidance Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at